Justin Ray
Psychiatric/Mental Health · Chesapeake, VANPI 1093013641
Payments from drug & device makers
Across 624 payments — averaging $204.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$58K
- AbbVie$42K
- Axsome Therapeutics, Inc.$23K
- Alkermes, Inc.$877
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$867
- Sunovion Pharmaceuticals Inc.$510
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$107,49184%
- Travel & lodging$7,8936%
- Food & beverage$11,9639%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 123 | $57,907 |
| AbbVie(2 entities) | 206 | $41,507 |
| Axsome Therapeutics, Inc. | 54 | $22,805 |
| Alkermes, Inc. | 34 | $877 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $867 |
| Sunovion Pharmaceuticals Inc. | 29 | $510 |
| Lundbeck LLC | 24 | $432 |
| Neurocrine Biosciences, Inc. | 13 | $341 |
| Otsuka America Pharmaceutical, Inc. | 21 | $338 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $313 |
| Teva Pharmaceuticals USA, Inc. | 11 | $250 |
| Vanda Pharmaceuticals Inc. | 7 | $218 |
| Supernus Pharmaceuticals, Inc. | 9 | $170 |
| Averitas Pharma Inc. | 1 | $150 |
| Neos Therapeutics, LP | 9 | $136 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $111 |
| Ironshore Pharmaceuticals Inc. | 6 | $104 |
| Almatica Pharma LLC | 6 | $96 |
| Corium, LLC | 6 | $81 |
| Tris Pharma Inc | 3 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $55 |
| Indivior Inc. | 1 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$127,413 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 40 | $129,667 |
| Abilify MaintenaAripiprazole | 25 | $73,771 |
| VraylarCariprazine Hcl | 49 | $70,419 |
| GeodonZiprasidone Hcl | 12 | $36,978 |
| TrileptalOxcarbazepine | 12 | $23,255 |
| CaplytaLumateperone Tosylate | 11 | $17,634 |
| Aripiprazole | 67 | $14,556 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $14,192 |
| AdderallDextroamphetamine/Amphetamine | 12 | $11,392 |
| QelbreeViloxazine Hcl | 13 | $8,951 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 30 | $6,612 |
| Haloperidol Decanoate | 74 | $5,975 |
| Lurasidone Hcl | 31 | $3,740 |
| Paliperidone ErPaliperidone | 21 | $3,363 |
| Divalproex Sodium ErDivalproex Sodium | 45 | $2,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $57,907 | $129,66740 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $338 | $73,77125 claims |
| AbbVieVraylar | $41,507 | $70,41949 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $867 | $17,63411 claims |
| Axsome Therapeutics, Inc.Auvelity | $22,805 | $14,19213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Adderall | $313 | $11,39212 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $170 | $8,95113 claims |
| Almatica Pharma LLCSertraline Hcl | $96 | $36651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Chesapeake
- Katia HallChesapeake$88K
- Amanda SnowChesapeake$13K
- Jennifer MelilloChesapeake$11K
- Keesha StewartChesapeake$7K
- Sophia ZwirnerChesapeake$7K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.